Sophia Genetics SA (SOPH): Price and Financial Metrics


Sophia Genetics SA (SOPH): $4.45

-0.04 (-0.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SOPH Stock Price Chart Interactive Chart >

Price chart for SOPH

SOPH Price/Volume Stats

Current price $4.45 52-week high $19.80
Prev. close $4.49 52-week low $3.99
Day low $4.31 Volume 18,573
Day high $4.54 Avg. volume 82,867
50-day MA $6.58 Dividend yield N/A
200-day MA $12.53 Market Cap 281.85M

Sophia Genetics SA (SOPH) Company Bio


Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.


SOPH Latest News Stream


Event/Time News Detail
Loading, please wait...

SOPH Latest Social Stream


Loading social stream, please wait...

View Full SOPH Social Stream

Latest SOPH News From Around the Web

Below are the latest news stories about SOPHiA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples.

Yahoo | February 24, 2022

First Japanese Institution to Utilize SOPHiA GENETICS'' Myeloid Plus Solution

BOSTON , LAUSANNE, Switzerland , and HIROSHIMA, Japan , Feb. 22, 2022 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH ), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan , to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan. With NGS for myeloid testing not widely available in Japan , a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the N...

Benzinga | February 22, 2022

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders.

Yahoo | February 22, 2022

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time.

GlobeNewswire | February 16, 2022

SOPHiA GENETICS (NASDAQ:SOPH) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 10, 2022

Read More 'SOPH' Stories Here

SOPH Price Returns

1-mo -41.52%
3-mo -64.26%
6-mo -69.20%
1-year N/A
3-year N/A
5-year N/A
YTD -68.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1444 seconds.